Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROfound trial of olaparib versus enzalutamide or abiraterone in metastatic castration-resistant prostate cancer
MOH_2017-04-18_000316Phase 3Not yet recruiting
- Sponsor
- AstraZeneca
- Start
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of olaparib, enzalutamide and abiraterone in metastatic castration-resistant prostate cancer (mCRPC) (2 arms), sponsored by AstraZeneca. Planned start Mar 2017; status: not yet recruiting.
02
Drugs
olaparibenzalutamideabiraterone
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on MOH_2017-04-18_000316.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-04-18_000316.